官方服务：
资源简介：
List of CHMs for NSCLC with immunotherapy, categorized by study
应用场景：
创建时间：
2026-01-14
相关数据集
Adjunctive use of modified Yunu-Jian in the non-surgical treatment of male smokers with chronic periodontitis: a randomized double-blind, placebo-controlled clinical trial
Background: Yunu-Jian (YJ) is a Chinese medicine (CM) heat purging formula, which is used to reduce wei huo (stomach-heat, SH) and enrich shen yin (kidney-yin, KY). This formula is also commonly used
NIAID Data Ecosystem50
ena-DATASET-JHU-UAD-14-09-2018-18:13:52:593-711 - samples
The dataset for Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer includes 17 bam files from next-generation sequencing on the Illumina HiSeq2500. The b
NIAID Data Ecosystem30
Impaired HLA Class 1 Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. The purpose of this study was to investigate whether alterations in genes encoding components of the HLA
NIAID Data Ecosystem20
A randomized, double-blind, placebo-controlled study of Fuzheng Kang’ai Decoction combined with PD-1 inhibitor in the treatment of phlegm-damp-type advanced non-small cell lung cancer
Interventions: Experimental group:PD-1 Inhibitor + Fuzheng Kang’ai Fang Granules;Control group:PD-1 Inhibitor + Fuzheng Kang’ai Fang Placebo Primary outcome(s): progression free survival Study Design:
NIAID Data Ecosystem40
Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer
The benefit of programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors remains unclear in non-small cell lung cancer (NSCLC) patients with poor performance sta
Figshare2025-04-11 更新20
